GB9711125D0 - Novel cyanoguanidines - Google Patents

Novel cyanoguanidines

Info

Publication number
GB9711125D0
GB9711125D0 GBGB9711125.6A GB9711125A GB9711125D0 GB 9711125 D0 GB9711125 D0 GB 9711125D0 GB 9711125 A GB9711125 A GB 9711125A GB 9711125 D0 GB9711125 D0 GB 9711125D0
Authority
GB
United Kingdom
Prior art keywords
stands
alkoxycarbonyl
trifluoromethyl
carboxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9711125.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMACEUTICAL PROD Ltd
Leo Pharma AS
Original Assignee
PHARMACEUTICAL PROD Ltd
Leo Pharmaceutical Products Ltd AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMACEUTICAL PROD Ltd, Leo Pharmaceutical Products Ltd AS filed Critical PHARMACEUTICAL PROD Ltd
Priority to GBGB9711125.6A priority Critical patent/GB9711125D0/en
Publication of GB9711125D0 publication Critical patent/GB9711125D0/en
Priority to PL98337030A priority patent/PL190314B1/pl
Priority to RO99-01251A priority patent/RO120541B1/ro
Priority to AU76386/98A priority patent/AU733142B2/en
Priority to RU99128082/04A priority patent/RU2195453C2/ru
Priority to DE69818041T priority patent/DE69818041T2/de
Priority to KR10-1999-7011131A priority patent/KR100496220B1/ko
Priority to CN98805595A priority patent/CN1116283C/zh
Priority to HK00106580.3A priority patent/HK1027562B/xx
Priority to NZ501071A priority patent/NZ501071A/en
Priority to PCT/DK1998/000196 priority patent/WO1998054144A1/en
Priority to AT98924055T priority patent/ATE249438T1/de
Priority to PT98924055T priority patent/PT984938E/pt
Priority to CA002292895A priority patent/CA2292895C/en
Priority to CZ19994234A priority patent/CZ294842B6/cs
Priority to US09/424,632 priority patent/US6346541B1/en
Priority to EP98924055A priority patent/EP0984938B1/en
Priority to ES98924055T priority patent/ES2206932T3/es
Priority to JP50011499A priority patent/JP4408455B2/ja
Priority to DK98924055T priority patent/DK0984938T3/da
Priority to HU0002921A priority patent/HUP0002921A3/hu
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB9711125.6A 1997-05-29 1997-05-29 Novel cyanoguanidines Pending GB9711125D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB9711125.6A GB9711125D0 (en) 1997-05-29 1997-05-29 Novel cyanoguanidines
HU0002921A HUP0002921A3 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
PCT/DK1998/000196 WO1998054144A1 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors
PT98924055T PT984938E (pt) 1997-05-29 1998-05-15 Cianoguanidinas como inibidores da proliferacao celular
AU76386/98A AU733142B2 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors
RU99128082/04A RU2195453C2 (ru) 1997-05-29 1998-05-15 Цианогуанидины, способы их получения и фармацевтический препарат на их основе
DE69818041T DE69818041T2 (de) 1997-05-29 1998-05-15 Cyanoguanidine als zellproliferation inhibitoren
KR10-1999-7011131A KR100496220B1 (ko) 1997-05-29 1998-05-15 세포 증식 억제제로서의 시아노구아니딘
CN98805595A CN1116283C (zh) 1997-05-29 1998-05-15 作为细胞增殖抑制剂的氰基胍
HK00106580.3A HK1027562B (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors
NZ501071A NZ501071A (en) 1997-05-29 1998-05-15 Cyanoguanidines such as N-cyano-N'-(5-phenylaminocarbonylpentyl)-N'-4-pyridylguanidine for treating skin cancer or cancer cells
PL98337030A PL190314B1 (pl) 1997-05-29 1998-05-15 Cyjanoguanidyny jako inhibitory proliferacji komórki, preparat farmaceutyczny, sposób wytwarzania cyjanoguanidyn oraz ich zastosowanie
AT98924055T ATE249438T1 (de) 1997-05-29 1998-05-15 Cyanoguanidine als zellproliferation inhibitoren
RO99-01251A RO120541B1 (ro) 1997-05-29 1998-05-15 Derivaţi de cianoguanidină, ca inhibitori ai proliferării celulelor
CA002292895A CA2292895C (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors
CZ19994234A CZ294842B6 (cs) 1997-05-29 1998-05-15 Kyanoguanidiny, způsob jejich přípravy a použití a farmaceutické přípravky s jejich obsahem
US09/424,632 US6346541B1 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors
EP98924055A EP0984938B1 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors
ES98924055T ES2206932T3 (es) 1997-05-29 1998-05-15 Cianoguanidinas como inhibidores de la proliferacion celular.
JP50011499A JP4408455B2 (ja) 1997-05-29 1998-05-15 細胞増殖抑制剤としてのシアノグアニジン
DK98924055T DK0984938T3 (da) 1997-05-29 1998-05-15 Cyanoguanidiner som celleproliferationsinhibitorer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9711125.6A GB9711125D0 (en) 1997-05-29 1997-05-29 Novel cyanoguanidines

Publications (1)

Publication Number Publication Date
GB9711125D0 true GB9711125D0 (en) 1997-07-23

Family

ID=10813255

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9711125.6A Pending GB9711125D0 (en) 1997-05-29 1997-05-29 Novel cyanoguanidines

Country Status (20)

Country Link
US (1) US6346541B1 (https=)
EP (1) EP0984938B1 (https=)
JP (1) JP4408455B2 (https=)
KR (1) KR100496220B1 (https=)
CN (1) CN1116283C (https=)
AT (1) ATE249438T1 (https=)
AU (1) AU733142B2 (https=)
CA (1) CA2292895C (https=)
CZ (1) CZ294842B6 (https=)
DE (1) DE69818041T2 (https=)
DK (1) DK0984938T3 (https=)
ES (1) ES2206932T3 (https=)
GB (1) GB9711125D0 (https=)
HU (1) HUP0002921A3 (https=)
NZ (1) NZ501071A (https=)
PL (1) PL190314B1 (https=)
PT (1) PT984938E (https=)
RO (1) RO120541B1 (https=)
RU (1) RU2195453C2 (https=)
WO (1) WO1998054144A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU1494702A (en) 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
ATE442362T1 (de) * 2001-05-24 2009-09-15 Leo Pharma As Pyridylcyanoguanidin verbindungen
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
BR0309988A (pt) * 2002-05-17 2005-02-22 Leo Pharma As Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto
CA2485351C (en) * 2002-05-17 2011-12-06 Leo Pharma A/S Cyanoguanidine prodrugs
WO2006037468A1 (en) * 2004-09-30 2006-04-13 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv reverse transcriptase inhibitors
ES2572777T3 (es) 2004-12-22 2016-06-02 Leo Pharma A/S Compuestos novedosos de cianoguanidina
US7423042B2 (en) * 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
WO2009072004A2 (en) 2007-09-26 2009-06-11 Gemin X Pharmaceuticals Canada, Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
WO2009086835A1 (en) * 2008-01-11 2009-07-16 Topotarget A/S Novel cyanoguanidines
RU2011111728A (ru) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
CA2751495C (en) 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
JP2013540781A (ja) 2010-10-26 2013-11-07 ティエンジン ホーメイ バイオ−テック カンパニー， リミテッド Ｎ−（６−（４−クロロフェノキシ）ヘキシル）−ｎ’−シアノ−ｎ’’−（４−ピリジル）グアニジンの結晶多形とその製造及び使用
CA3039589A1 (en) 2016-10-18 2018-04-26 Seattle Genetics, Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
CA3060206A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004499A1 (en) * 1992-08-13 1994-03-03 The Upjohn Company Cyanoguanidines as potassium channel blockers
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
MX9603051A (es) * 1994-01-28 1997-06-28 Upjohn Co Cianoguanidinas como bloqueadores del canal-k.

Also Published As

Publication number Publication date
NZ501071A (en) 2001-08-31
DE69818041T2 (de) 2004-07-08
PL337030A1 (en) 2000-07-31
CA2292895C (en) 2007-03-06
EP0984938B1 (en) 2003-09-10
ES2206932T3 (es) 2004-05-16
PT984938E (pt) 2004-02-27
CN1258279A (zh) 2000-06-28
AU7638698A (en) 1998-12-30
HUP0002921A3 (en) 2002-10-28
RO120541B1 (ro) 2006-03-30
US6346541B1 (en) 2002-02-12
WO1998054144A1 (en) 1998-12-03
KR100496220B1 (ko) 2005-06-21
HUP0002921A2 (hu) 2001-01-29
CZ9904234A3 (cs) 2001-02-14
CN1116283C (zh) 2003-07-30
CZ294842B6 (cs) 2005-03-16
EP0984938A1 (en) 2000-03-15
DE69818041D1 (de) 2003-10-16
CA2292895A1 (en) 1998-12-03
JP2001526694A (ja) 2001-12-18
ATE249438T1 (de) 2003-09-15
PL190314B1 (pl) 2005-11-30
HK1027562A1 (en) 2001-01-19
AU733142B2 (en) 2001-05-10
RU2195453C2 (ru) 2002-12-27
DK0984938T3 (da) 2004-01-12
JP4408455B2 (ja) 2010-02-03
KR20010013148A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
GB9711125D0 (en) Novel cyanoguanidines
NZ508990A (en) Pyrazoline derivatives, their preparation and application as medicaments
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
GB2369360A (en) 5-cyano-2-aminopyrimidine derivatives
MY112232A (en) Indole derivatives
MXPA05006740A (es) Imidazoquinolinas arilo-sustituidas.
PL338452A1 (en) Novel substituted 6-phenylphenatridines
IL108769A0 (en) Spirocyclic piperidine derivatives
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
WO2001062705A3 (en) Aminoalcohol derivatives
BG103867A (en) Cyanoguanidines as cell proliferation inhibitors
MXPA03009750A (es) Compuestos quimicos.
WO2004022528A3 (en) Arylglycine derivatives and their use as glycine transport inhibitors
IL158574A0 (en) Novel pyridyl cyanoguanidine compounds
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
GB9711123D0 (en) Novel cyanoguanidines
WO2002014281A8 (en) Pyridine derivatives as inhibitors of p38
BR9710230A (pt) Derivados de indol para o tratamento de osteoporose
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
ZA974470B (en) Hexahydro-pyrido[4,3-b]indole derivatives
IL180312A0 (en) Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 recepor antagonists
EA200001009A1 (ru) Производные пиридина, ингибирующие фосфодиэстеразу iv
YU73200A (sh) 2-aminopiridini koji sadrže spojene ciklične supstituente kao inhibitori nitro oksid sintaze
MXPA04004450A (es) Nuevos compuestos y composiciones como inhibidores de catepsina s.
IL123692A0 (en) Phenanthridine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same